About us

We are building the next-generation of pain 
killers

With over 25 years in research pain and pharmaceutical industry we are dedicated to researching new treatments for serious diseases in areas with significant unmet medical needs—and to ensuring these solutions reach the patients who need them most.

Our vision

At Dolinnov, our vision is to revolutionize patients' lives and transform the landscape of pain management through cutting-edge research and innovation.

Our ambition is to pioneer the first L-ASO therapies for severe and unbearable chronic pain, currently reserved for ultra-rare diseases.

Precision medicine
Broad Potential
application
Outstanding Proof
of Efficacy

Our operating team

Grégoire Serra
CEO & Co-Founder
Grégoire Serra
CEO & Co-Founder

Grégoire Serra combines a unique dual expertise in science and law, equipping him to skillfully navigate the complex intersection of research, innovation, and regulatory frameworks. With broad experience in pharmaceutical partnerships, technology transfer, and intellectual property, he plays a pivotal role in fostering strategic collaborations and accelerating the financing process to transform academic projects into clinical realities.

Dr. Stéphanie
Venteo
CSO & Co-founder
Dr. Stéphanie
Venteo
CSO & Co-founder

Dr. Stéphanie Ventéo holds a PhD in Neuroscience and serves as a Research Engineer at INSERM, where she leads her research group at the Institute for Neurosciences of Montpellier (INM). 

With over 25 years of experience, Dr. Ventéo has dedicated her career to advancing the understanding of the physiology and pathology of the somatosensory system, with a particular focus on chronic pain. Her extensive expertise and innovative research contribute to the development of groundbreaking solutions in pain management.

Jean Philippe Annereau
R&D Strategy & Co-founder
Jean Philippe Annereau
R&D Strategy & Co-founder

Dr. Jean-Philippe Annereau, PhD from École Polytechnique, brings over 20 years of expertise in the pharmaceutical industry, focusing on oncology and rare diseases. As the former CEO of Alexion R&D France and Medetia Pharmaceuticals, he has a proven track record in driving innovation.

At Dolinnov, Dr. Annereau serves as a key strategist, leveraging his deep industry knowledge to shape the company’s R&D direction and accelerate the development of transformative pain management solutions.

Our scientific advisory board

Pr. Céline Greco
Physician-researcher
Pr. Céline Greco
Physician-researcher

Pr. Céline Greco is the Head of the Pain and Palliative Medicine Department at Necker-Enfants Malades Hospital, one of France’s most renowned pediatric centers. She is also a member of the National Council for Child Protection (CNPE). As a physician-researcher, Pr. Greco is deeply committed to improving the quality of life for children, particularly those facing chronic pain or life-limiting conditions. Her expertise in pediatric pain management and palliative care combines clinical excellence with innovative research

Pr. Nadine Attal
Neurologist
Pr. Nadine Attal
Neurologist

Nadine Attal is a neurologist and pain specialist, professor of therapeutics and pain medicine, Head of the Pain Evaluation and Treatment Center at Ambroise Paré Hospital in France and deputy director of the INSERM U987 research Unit directed by D Bouhassira, focusing on pathophysiology and clinical pharmacology of pain.
A key figure in neuropathic pain research, PR. Attal has chaired international guidelines, authored over 170 peer reviewed scientific articles, and led numerous clinical trials. Her work has earned her several prestigious awards, including Chevalier de la Légion d’Honneur (knight), a biology prize from French Academy of Science and the first Axel Kahn « douleur et cancer » award.

Dr. Alain Toledano
Oncologist and radiotherapist
Dr. Alain Toledano
Oncologist and radiotherapist

Dr. Alain Toledano is a prominent French oncologist and radiotherapist. He is the founder and president of the Institut Rafaël, France’s first integrative health center dedicated to post-cancer care. He serves as Medical Director of the Hartmann Institute of Radio-Surgery and chairs the medical board of the Oncology Institute of Hauts-de-Seine. Dr. Toledano also leads the Research Chair in Integrative Health at the Conservatoire National des Arts et Métiers (CNAM). A recognized expert in his field, he has held leadership roles in top medical institutions and continues to drive innovation in patient care.

Pr. Philippe Barthelemy
Expert in molecular and nano-chemistry
Pr. Philippe Barthelemy
Expert in molecular and nano-chemistry

Philippe Barthélémy is a professor and Director of the ChemBioPharm team at the University of Bordeaux and the ARNA Laboratory (INSERM U1212/CNRS UMR 5320). He earned a PhD in Chemistry from the University of Montpellier II in 1993 and held positions at Emory, Duke, and Avignon before joining Bordeaux in 2005. With over 150 publications, 21 patents, and 100+ conference presentations, he is a leading expert in molecular and nano-chemistry.

Dr. François Hubert
Expert toxicology
Dr. François Hubert
Expert toxicology

With over 30 years of experience in experimental and regulatory toxicology, including recognition as a EUROTOX Toxicologist since 1997, François Hubert has served on national and international committees such as AFSSAPS, WHO, and the French Ministries of Health and Agriculture. A founding member of the National Committee on Animal Experimentation, they have contributed to toxicological evaluations for cosmetics, biocides, plant protection products, and fertilizers, ensuring regulatory compliance and product safety.

An innovation-driven team

World-class and experienced team with recognized 
KOL Pain Management given its experience in the development of pain treatments

What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.

Jean-Philippe Annereau, R&D strategy & Co-Founder

It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.

Dr. Stéphanie Venteo, CSO & Co-founder

Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.

Gregoire Serra, CEO & Co-founder

Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.

Alix Pradère, Investor

Dolinnov is a unique opportunity to convert a high-level academic scientific project into a groundbreaking enterprise. I am committed to dedicating my full energy to turning this project into a clinical reality that will make a difference for patients.

Gregoire Serra, CEO & Co-founder

It is the extraordinary motivation of a researcher to transform a groundbreaking academic discovery from my thesis into a preclinical reality, with the goal of revolutionizing patient care and advancing the frontiers of medicine.

Dr. Stéphanie Venteo, CSO & Co-founder

What immediately inspired me to join this project was its groundbreaking approach to targeting this mechanism—a causal and 'circuit-breaking' strategy for pain management. Combined with the exceptional quality of the underlying science, it redefines treatment paradigms, effectively addressing the primary barriers to patient care.

Jean-Philippe Annereau, R&D Strategy & Co-founder

Investing in Dolinnov is above all about supporting a highly mature, scientific disruptive project with the potential to deliver game-changing treatment solutions. It also means placing trust in a strong and dedicated team capable of making this vision a clinical reality.

Alix Pradère, Investor
Trust in our project
Trust in our project
Trust in our project
Trust in our project

Five reasons to support us in this journey

A patient driven Biotech

At Dolinnov, patients are at the heart of our mission. Through close collaboration with patient associations, we ensure our innovations address real needs and improve lives.

Uniting with shared mission

We unite patients, investors, medical specialists, and experts around our project, addressing this universal challenge.

Impact-Driven Investors

First investors back a project focused on innovation and positive change for patients.

A Multidisciplinary Team Driving Innovation

Experienced team driving the project to new heights.

A New Paradigm in Pain Management

We are transforming pain treatment with a safer, non-opioid solution.
+1.5M€ deployed

already deployed on this project

Partners supporting the project

Ready to deliver the next generation of pain killers ? Get in touch !

Contact us